Success Stories: EB-1A Petition Approved for Associate Research Scientist in the Field of Drug Discovery in Just 8 Days, Special Thanks to PP

 

Client’s Testimonial:

“Thanks a lot to your team for helping me in this case.”


On March 10th, 2020, we received another EB-1A (Alien of Extraordinary Ability) approval for an Associate Research Scientist in the Field of Drug Discovery (Approval Notice).


General Field: Drug Discovery

Position at the Time of Case Filing: Associate Research Scientist

Country of Origin: India

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: March 10th, 2020

Processing Time: 8 days (PP requested)


Case Summary:

Our client, an associate research scientist from India who specializes in the field of drug discovery focusing on utilizing medicinal chemistry and natural products chemistry techniques to discover new drugs for cancer, infectious diseases and disorders of the heart and lungs, hired our firm to present a convincing EB-1A case to the USCIS.

By submitting evidence of the research success – 25 peer-reviewed scientific articles, one book chapter, and one patent and his experience of judging the work of his peers for 26 times, we established the fact that our client is an extraordinary researcher who deserves to remain in the United States to conduct his impactful research. We also detailed the 491 times his work was cited by other leading and influential researchers around the world. Since EB-1A is one of the toughest I-140 categories, we made sure that we thoroughly presented our client’s achievements in a clear and concise manner.

The customized EB-1A petition packet which we arranged for our client contained an array of information that highlighted his research achievements. We also included several recommendation letters contributed by other well-known figures in the field. One of the recommenders stated that: “Drug discovery is an important field that affects us all. Developing novel ways of treating diseases improves public health and quality of life. This is an urgent priority for the field, and [client’s] research is on the cutting edge of this front. His research is aiding in the advancement of drug development, and it is in the United States’ best interest to support his work.”

In addition to carefully assembling the required documents to file the EB-1A petition on behalf of our client, our team has included customized figures and tables for visualization to indicate that our client’s publications have been cited at a much higher rate than those of other researchers in the field, distinguishing him from his peers. The visual presentation of the data has indeed further demonstrated and supported the argument in the petition letter drafted by us.

With abundant experience working with clients in virtually all fields of expertise, we are well equipped to handle every circumstance that might arise when filing an I-140 immigration petition. We truly appreciate our client for trusting us with the preparation of his EB-1A case and for giving us an opportunity to be a part of his success story.


North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.


approval_table_2017

Approval Notices: https://www.wegreened.com/eb1_niw_approvals

Success Stories: https://www.wegreened.com/blog/

Website: www.wegreened.com

Free evaluation: https://www.wegreened.com/Free-Evaluation

Tel: 888.666.0969 (Toll Free)


To see more clients’ testimonials and approvals, please refer to:

Client's Testimonials

Approval Notices

To Learn More About Your Options CLICK HERE


Copyright © North America Immigration Law GroupWeGreened.com, All Rights Reserved.